ReviewDrug discovery today2007
Orphan nuclear receptors in drug discovery.
Review in Drug discovery today, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 85 citations in OpenAlex.
- Review
- Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer.Oncogene · 2021Review
- The Paradoxical Roles of Orphan Nuclear Receptor 4A (NR4A) in Cancer.Molecular cancer research : MCR · 2021Review
- Nuclear Receptors in Asthma: Empowering Classical Molecules Against a Contemporary Ailment.Frontiers in immunology · 2020Review
- Signaling through non-membrane nuclear phosphoinositide binding proteins in human health and disease.Journal of lipid research · 2019Review
- Nanoformulations of natural products for management of metabolic syndrome.International journal of nanomedicine · 2019Review
- NR4A2 protects cardiomyocytes against myocardial infarction injury by promoting autophagy.Cell death discovery · 2018Article
- The effects of cytosporone-B, a novel antifibrotic agent, on vocal fold fibroblasts.The Laryngoscope · 2018Article
- Orphan Nuclear Receptors in Colorectal Cancer.Pathology oncology research : POR · 2018Review
- TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.Clinical pharmacology and therapeutics · 2018Article
- The Nuclear Receptor Field: A Historical Overview and Future Challenges.Nuclear receptor research · 2018Article
- Obstacles to Brain Tumor Therapy: Key ABC Transporters.International journal of molecular sciences · 2017Review
- Nurr1 and PPARγ protect PC12 cells against MPP(+) toxicity: involvement of selective genes, anti-inflammatory, ROS generation, and antimitochondrial impairment.Molecular and cellular biochemistry · 2016Article
- Nuclear Receptor Nr4a2 Promotes Alternative Polarization of Macrophages and Confers Protection in Sepsis.The Journal of biological chemistry · 2015Article
- Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs.Meta gene · 2015Article
- Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Minireview: role of orphan nuclear receptors in cancer and potential as drug targets.Molecular endocrinology (Baltimore, Md.) · 2014Review
- A chemogenomics based approach for deorphanization of testicular receptor 4: An orphan receptor of nuclear receptor superfamily.Journal of natural science, biology, and medicine · 2013Review
- Article
- Minireview: the role of nuclear receptors in photoreceptor differentiation and disease.Molecular endocrinology (Baltimore, Md.) · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Orphan nuclear receptors provide a unique resource for uncovering novel regulatory systems that impact human health and also provide drug targets for a variety of human diseases. Ligands of nuclear receptors have been used in several important therapeutic areas, such as breast cancers, skin disorders and diabetes. Orphan nuclear receptors, therefore, represent a tremendous opportunity in understanding and treating human diseases. Here, I highlight recent advances in the use of orphan nuclear receptors and their potential as targets for drug discovery in diabetes, obesity, neurodegenerative diseases and other related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.